Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Adhd

    Current Location

    Search
    Adhd
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    6 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Tampa, FL

    12 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Baltimore, MD

    15 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Albuquerque, NM

    Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Boston, MA

    Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near Long Beach, CA

    Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near San Diego, CA

    14 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Anaheim, CA

    13 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Cincinnati, OH

    Top Cholesterol Clinical Trials

    Top Cardiovascular Clinical Trials

    Top Asd Clinical Trials

    Top Eoe Clinical Trials

    By Trial

    MomMA Intervention for ADHD

    tDCS for ADHD

    EB-1020 for ADHD

    Motor Attention Training for ADHD

    Behavioral Parenting Intervention for ADHD

    Behavior Therapy for ADHD in Primary Care

    Digital Health Intervention for ADHD

    Air Pollution Exposure and Risk of ADHD in Youth

    GSK4381562 for Cancer

    Healthy Lifestyle Program for Obesity Prevention in Hispanic Families

    JCAR017 for Chronic Leukemia or Lymphoma

    Calcium and Calcitriol Protocols for Hypoparathyroidism

    Related Searches

    Top Low-back-pain Clinical Trials

    Combination Therapy for Ulcerative Colitis

    Text Messaging for Vaping

    SABR for Breast Cancer

    Olezarsen for Chylomicronemia Syndrome

    Brain Monitoring for Speech Perception

    Imvotamab for Lupus

    Stem Cell Transplant for Sickle Cell Disease

    Nutrition App for Female Soccer Players

    MK-2828 for Type 2 Diabetes

    Enhanced Primary Care and Resilience Clinic for Early Life Adversity and Caregiver Stress

    Transcranial Electrical Stimulation for Mild Cognitive Impairment

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      106 Adhd Trials Near You

      Power is an online platform that helps thousands of Adhd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Stimulant Medications for ADHD in Autism Spectrum Disorder

      Columbus, Ohio
      This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Unstable Medications, Others
      Must Not Be Taking:ADHD Medications

      500 Participants Needed

      Azstarys® for ADHD

      Dayton, Ohio
      The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:4 - 5

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Major Depression, Autism, Others
      Must Not Be Taking:Anticonvulsants, Others

      123 Participants Needed

      Centanafadine for ADHD

      West Chester, Ohio
      This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:4 - 18

      Key Eligibility Criteria

      Disqualifiers:Tourette's, Severe Anxiety, Psychosis, Autism, MDD, Others

      680 Participants Needed

      SPN-812 for ADHD

      West Chester, Ohio
      This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:48 - 69

      Key Eligibility Criteria

      Disqualifiers:Major Psychiatric, Neurological Disorders, Others
      Must Not Be Taking:CYP1A2 Substrates

      286 Participants Needed

      Evening Dosed Methylphenidate for ADHD

      Cincinnati, Ohio
      This study will evaluate the efficacy, safety and pharmacokinetics of HLD200 (20 mg and 40 mg) in children aged 4 to 5 years with ADHD.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:4 - 5

      Key Eligibility Criteria

      Disqualifiers:Cardiac Conditions, Seizure Disorder, Psychosis, Others
      Must Not Be Taking:Antidepressants, Mood Stabilizers, Antipsychotics

      168 Participants Needed

      Methylphenidate for ADHD

      Cincinnati, Ohio
      Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in childhood. Children with ADHD struggle in school due to problems with attention and high levels of impulsivity and hyperactivity. They are at substantially increased risk for long-term difficulties into adulthood, including academic underachievement, substance abuse, and criminal behavior. The diagnosis of ADHD, which is based on subjective ratings by parents and teachers, likely results from multiple different, overlapping differences in circuits of the brain responsible for attention and impulse control. However, we do not have any scientific or clinical tests that allow us to understand these circuits. In an effort to improve ADHD outcomes, we have used a technology called Transcranial Magnetic Stimulation (TMS) to identify highly reliable measurements of brain function. We have identified two very promising measures that are abnormal in children with ADHD and, importantly, also predict the severity of ADHD behaviors. The goal of this project is to determine if these two TMS measurements could be used to help better guide ADHD treatment. To do this, we will perform three investigations in 8 to 12 year old children to determine: 1) test-retest reliability; 2) pharmacologic responsiveness; and 3) correlations with two domains of function relevant to ADHD: "Cognitive Control" and "Emotional Valence." Through these investigations, we aim to determine whether these two TMS brain measures are reliable and meaningful enough to be used to help improve precision of individually-targeted and effective ADHD treatments.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:8 - 12

      Key Eligibility Criteria

      Disqualifiers:Autism, Epilepsy, Bipolar, Others
      Must Not Be Taking:Antidepressants, Non-stimulants, Dopamine Blockers, Mood Stabilizers

      214 Participants Needed

      TAK-503 for ADHD

      Cincinnati, Ohio
      The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:PTSD, Bipolar, Substance Abuse, Others
      Must Not Be Taking:Sedating Antihistamines, Decongestant Sympathomimetics

      396 Participants Needed

      Virtual Reality Training for ADHD

      Cincinnati, Ohio
      Teens with Attention-Deficit/Hyperactivity Disorder (ADHD) have high rates of negative driving outcomes, including motor vehicle crashes, which may be caused by visual inattention (i.e., looking away from the roadway to perform secondary tasks). Two versions of a driving intervention that trains teens to reduce instances of looking away from the roadway will be tested in teens with ADHD.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:16 - 19

      Key Eligibility Criteria

      Disqualifiers:Drug Dependence, Alcohol Dependence, Head Trauma, Others
      Must Not Be Taking:ADHD Medications, Psychotropic, Neuroleptic

      204 Participants Needed

      TMS for ADHD

      Cincinnati, Ohio
      ADHD children have abnormal inhibitory control, meaning they have trouble stopping themselves from doing something they should not do. This ability to control involves an area in the brain called the pre-supplementary motor area (pre-SMA). Scientists have previously shown that the pre-SMA is abnormal in ADHD patients. In this study, we will use Transcranial Magnetic Stimulation (TMS) to stimulate the pre-SMA and determine the effects on measures that are related to inhibitory control.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 17

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Brain Injury, Depression, Others
      Must Not Be Taking:Non-stimulants, Antipsychotics

      40 Participants Needed

      Personalized Medication for ADHD

      Cincinnati, Ohio
      The primary goal of the project is to test personalized medication experiments to inform decisions about future medication use. Our central hypothesis is that our intervention will lead to within subject increases in adolescent involvement in decision making and decreases in uncertainty about future medication use. The investigators view this open label trial as a pilot study to test the feasibility, acceptability, and preliminary efficacy of the medication experiment intervention and therefore warrants further testing in a future larger trial.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:11 - 15

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      30 Participants Needed

      Family Navigation for ADHD Treatment Adherence

      Cincinnati, Ohio
      ADHD is the most common pediatric neurodevelopmental disorder and is associated with significant long-term impairments. Current guidelines recommend stimulant medication and/or behavioral therapy as first-line treatments for ADHD. Despite evidence that consistent treatment is important for effectively managing ADHD symptoms, treatment adherence remains suboptimal and is especially problematic among minority children. Hypothesized reasons for racial/ethnic disparities in ADHD treatment include uncertainties about medication efficacy and side effects, distrust of the health care system, and decreased access to mental health services. This study aims to develop and test the I2-ART intervention to improve treatment adherence in minority (Latinx and African American) children with ADHD. The proposed study involves three ORBIT phases: During phase 1a, the investigators will conduct focus groups with key stakeholders (i.e., caregivers, clinicians, and family navigators, n=24) to identify and develop I2-ART's basic elements. Next, during phase 1b, the investigators will train four family navigators to implement I2-ART with caregivers of treatment-naïve children with ADHD (n=8-12) in order to determine feasibility and acceptability. In phase 2, the investigators will use phase 1b findings to modify I2-ART as needed, and then will evaluate the preliminary efficacy of the revised I2-ART (n=40), compared to the "usual care" control condition (n=20), on ADHD treatment adherence. The preliminary data collected during the proposed study will inform a subsequent R01 randomized controlled trial to examine I2-ART efficacy.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-English/Spanish Speakers

      108 Participants Needed

      Quillivant XR for ADHD in Down Syndrome

      Cincinnati, Ohio
      Children with Down syndrome (DS) have a 3-5 time greater prevalence of Attention Deficit Hyperactivity Disorder (ADHD) than typically developing (TD) children. Despite this higher risk of ADHD, rates of stimulant medication treatment are disproportionately low in children with DS+ADHD, even though stimulants are the most efficacious ADHD treatment and are recommended by consensus guidelines for use in children with intellectual disability and ADHD. The investigators propose the first randomized clinical trial (RCT) of stimulant medication in children with DS+ADHD. This RCT may provide evidence regarding the short- and long-term safety and efficacy of stimulant use in children with DS+ADHD, both with and without CHD. All children enrolled in the study will complete a comprehensive assessment battery evaluating ADHD diagnostic criteria, as well as behavioral, cognitive, academic, and functional impairments.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Psychoses, Bipolar, Organic Brain Injury, Heart Conditions, Severe OSA, Pregnancy, Others
      Must Not Be Taking:ADHD Stimulants, MAOIs

      100 Participants Needed

      Methylphenidate for Intellectual Disability and ADHD

      Cincinnati, Ohio
      This study is a randomized, double-blind, placebo-controlled, crossover trial of extended-release liquid methylphenidate (XRMPH) to evaluate the sensitivity of the NIH Toolbox Cognition Battery (NIHTB-CB) to changes in cognition in children and adolescents ages 6 to 17 with intellectual disability (D) and comorbid Attention Deficit Hyperactivity Disorder (ADHD). The sample will include 68 males or females (expected male: female ratio of 1.8:1 with ID and ADHD as determined by structured diagnostic interview and Conners 3 scores. Additional inclusion criteria will include Full Scale IQ above 50 and mental age greater than or equal to 3 years. In addition, participants must be able to complete NIHTB-CB testing and provide valid scores at baseline. After baseline testing, participants will then be randomized to drug or placebo in a 1:1 ratio (N=34 per group) at the end of the baseline visit. XRMPH in oral suspension supplied as Quillivant XR in 5 mg/ml (Tris Pharma, Monmouth Junction, NJ) will be the active treatment. The XRMPH or matching placebo will be started at a dose of 0.3 mg/kg/day and individually titrated over two weeks. Phone calls at the end of weeks 1, 2, and 3 will be used to collect adverse event and response data. If there is no evidence of side effects and ongoing symptoms of ADHD, the dose will be increased to 0.5 mg/kg/day at one week and 0.7 mg/kg/day at 2 weeks (maximum dose of 60 mg per day consistent with FDA labeled use in youth). The Clinical Global Impression (CGI) will be used as a guide to define optimal dose. If side effects occur the dose will be reduced to the dose level at which there were no side effects. Final optimal dose will be established by the end of week 3 and this will be maintained for 2 weeks until 5 weeks post randomization, at which time the follow-up parent and teacher Conners scales, NIHTB-CB, Go/No-Go, and PedsQL will be completed. Participants will have a washout period of 1 week, will then complete re-assessment at the second baseline, and then will cross over to the other treatment (Quillivant to placebo; placebo to Quillivant), also in a double-blind fashion. In the second treatment arm, patients will have the same titration, monitoring and treatment periods as in the first arm, again followed by repeated assessments at the conclusion of 5 weeks. The accrual of participants and number of visits is shown in the Timeline per 6-month period.

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 1
      Age:6 - 24

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Epilepsy, Bipolar, Psychosis, Others
      Must Not Be Taking:Stimulants

      68 Participants Needed

      Sleep-Focused Parenting Intervention for Preschoolers with ADHD

      New Castle, Pennsylvania
      The goal of this pilot clinical effectiveness trial is to compare a brief parent behavioral intervention (PBI) to a modified sleep focused PBI (SF-PBI) delivered by therapists in pediatric primary care for families of children 3-5 years old with sleep problems and early ADHD symptoms. The main aims are to: Aim 1: Demonstrate the acceptability, feasibility, and appropriateness of the sleep focused PBI (SF-PBI) delivered in pediatric primary care for preschool-aged children (3-5 years old) at elevated risk for ADHD. Aim 2: Examine change in target engagement (sleep) and ADHD symptoms among preschool-aged children at elevated risk for ADHD receiving SF-PBI compared to standard PBI.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:3 - 5

      Key Eligibility Criteria

      Disqualifiers:Narcolepsy, Obstructive Sleep Apnea, Others

      50 Participants Needed

      MomMA Intervention for ADHD

      Pittsburgh, Pennsylvania
      The goal of this study is to test a behavioral program for pregnant individuals with ADHD. This behavioral program focuses on skills for managing ADHD and related symptoms in pregnancy and postpartum. This pilot effectiveness-implementation trial aims to (1) preliminarily evaluate the MomMA behavioral intervention compared to treatment as usual (TAU) on clinical outcomes and (2) evaluate implementation outcomes, including feasibility and acceptability of clinic screening within existing OB workflows; assessment and intervention protocols; provider training/fidelity to manual; and all other study protocols from the perspective of real-world providers and participants.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Intellectual Disability, Bipolar, Others

      120 Participants Needed

      Transcranial Focused Ultrasound for Impulsivity

      Pittsburgh, Pennsylvania
      The investigators aim to examine the immediate effect of transcranial focused ultrasound (tFUS) on brain activity in healthy adults.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:MDD, Psychosis, Bipolar, Epilepsy, Others
      Must Not Be Taking:Psychotropics, Stimulants

      31 Participants Needed

      MomMA Intervention for ADHD

      Pittsburgh, Pennsylvania
      The study will develop and test a behavioral program for pregnant individuals with Attention-Deficit/Hyperactivity Disorder (ADHD). This behavioral program will include skills for managing ADHD and related symptoms during pregnancy and after delivery and will be taught by a behavioral therapist in OB care settings.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 55
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Intellectual Disability, Severe Mental Illness, High Risk Pregnancies, Others

      10 Participants Needed

      Interaction Training for Childhood Behavior

      Morgantown, West Virginia
      The goal of this behavioral, interventional clinical trial is to provide a specialized workshop training for dental providers (e.g., dentists, hygienists, assistants) to improve interactions with young children (2-10 years old) and parents/caregivers. The training is derived from a well-established behavior management program for preschoolers, Parent-Child Interaction Therapy (PCIT). The main questions it aims to answer are: * Change in behavior of dental providers * Acceptability of training by dental providers All participants will receive the same behavior training; however, one group will receive the training on a delayed schedule. Researchers will compare the immediate intervention and control group to see if the training was effective in the dental providers usage of skills.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Autism, Others

      264 Participants Needed

      Sensory Intervention for Sleep Issues in ADHD

      Pittsburgh, Pennsylvania
      The goal of this study is test the hypothesis that sleep problems for children with ADHD are linked to sensory over-responsivity, a type of sensory processing difference that causes a person to interpret daily sensory input as stressful. This study examines the impact of sensory over-responsivity on bedtime arousal levels in 30 children with ADHD (ages 6-13). We will also test a bedtime intervention targeting sensory over-responsivity at bedtime and examine how it impacts bedtime arousal levels and sleep difficulties.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:6 - 13

      Key Eligibility Criteria

      Disqualifiers:Sleep Apnea, Narcolepsy, Depression, Others

      30 Participants Needed

      Digital Therapy Apps for Childhood Behavior Problems

      Pittsburgh, Pennsylvania
      This trial tests a smartphone app called UseIt! to help parents manage their children's disruptive behaviors. The app can be used alone or with help from a coach. It teaches parents effective behavior management techniques.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 8

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Major Depression, Pervasive Developmental, Others

      324 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Adhd Trial

      Implementation Support Strategies for Disruptive Behaviors

      Pittsburgh, Pennsylvania
      In a prior application (MH064372), the investigators' treatment research program (Services for Kids In Primary-care, SKIP) developed and tested a chronic care model-based intervention, called Doctor Office Collaborative Care (DOCC), that was found to be effective in the management of childhood behavior problems and comorbid ADHD. In the "SKIP for PA Study", the investigators propose to conduct a randomized clinical trial to evaluate the effects of team- and practice leadership-level implementation strategies designed to enhance the use and uptake of DOCC in diverse pediatric primary care offices.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Already Enrolled Caregiver

      450 Participants Needed

      Gameplay Therapy for Attention Deficit Hyperactivity Disorder (ADHD)

      Rochester Hills, Michigan
      This trial is testing a video game that adults with ADHD can play at home to help manage their symptoms. The game aims to improve attention and reduce hyperactivity by training the brain. Researchers are studying if this new approach is safe and effective. The Secret Trail of Moon (TSTM) is a virtual reality game designed for cognitive training related to core ADHD symptoms and executive dysfunction.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:22 - 55

      Key Eligibility Criteria

      Disqualifiers:PTSD, Schizophrenia, Bipolar, Autism, Others
      Must Be Taking:ADHD Medication

      194 Participants Needed

      Dyanavel XR for ADHD and Fatigue

      Rochester Hills, Michigan
      The goal of this clinical trial is to study the impact of Dyanavel on co-occuring fatigue in adults with Attention Deficit/Hyperactivity Disorder. The main question it aims to answer is whether Dyanavel XR leads to a statistically significant reduction in fatigue compared to placebo, as measured by the Fatigue Symptom Inventory.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Unstable Psychiatric, Heart Disease, Others
      Must Not Be Taking:CNS Stimulants, MAOIs

      50 Participants Needed

      Sertraline for Anxiety in Neurodevelopmental Disorders

      London, Ontario
      There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs. More research is needed to confirm whether or not sertraline could help improve anxiety in children and youth with common and rare neurodevelopmental conditions. This is a pilot study, in which we plan to estimate the effect size of reduction in anxiety of sertraline vs. placebo. across rare and common neurodevelopmental disorders, and determine the best measure(s) to be used as a primary transdiagnostic outcome measure of anxiety, as well as diagnosis specific measures in future, larger-scale clinical trials of anxiety in NDDs.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:8 - 17

      Key Eligibility Criteria

      Disqualifiers:Diabetes, HIV, Hepatitis, Others
      Must Not Be Taking:SSRIs, MAOIs, Pimozide, Others

      130 Participants Needed

      Emotional Regulation Intervention for Adolescents

      Blacksburg, Virginia
      This study consists of a randomized controlled trial assessing the acceptability, feasibility, and efficacy of the RELAX (Regulating Emotions Like An eXpert) Intervention. Following randomization, 30 families will receive the RELAX intervention and 30 families will receive psychoeducational materials as part of a control condition. Additionally, 10 families from the RELAX condition will participate in a pilot study and focus groups to give feedback on developed smartphone apps to support skill use during and following completion of RELAX.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:11 - 16

      Key Eligibility Criteria

      Disqualifiers:No ADHD, Age Outside 11-16, Others

      60 Participants Needed

      BUILT Family Lifestyle Program for ADHD

      Chicago, Illinois
      This trial tests the BUILT program, an online course for families in Chicago Park District programs. It aims to improve children's health and behavior through better food, sleep, and exercise routines. Families will participate in challenges to build these healthy habits.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:6 - 12

      Key Eligibility Criteria

      Disqualifiers:Age, Aerobic Conditions, Enrollment, Others

      316 Participants Needed

      Specific Trunk Interventions for Cerebral Palsy

      Chicago, Illinois
      Determine the effect of repeated pelvis perturbation training on trunk posture and locomotor function in children with CP.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:4 - 12

      Key Eligibility Criteria

      Disqualifiers:Severe Contractures, Fractures, Cardiovascular Instability, Others

      44 Participants Needed

      START Program for ADHD

      Chicago, Illinois
      The randomized control trial (RCT) study includes 2 aims; one being to test whether START increases access to treatment for ADHD. Investigators believe the intervention group will demonstrate improved treatment engagement and access to all treatments compared to controls. The second aim is to explore whether START leads to functional improvements across home, social and academic domains for the child and family. Investigators believe the intervention group will show better functioning including improved family and peer relationships and reduced parent stress compared to controls. Before taking part in our study all participants will undergo a psychiatric evaluation. Eligible participants will be randomized to START while controls receive a pamphlet with ADHD information. Students and staff with related experience who are not mental health professionals will be trained to deliver START. START includes 6 modules, typically delivered over 6 sessions.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:6 - 12

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Psychotic Symptoms, Others

      106 Participants Needed

      Video Game Therapy for ADHD

      Hamilton, Ontario
      Adults who have attention deficit hyperactivity disorder (ADHD) suffer from significant occupational, academic and social problems, many of which are believed to be a result of problems with executive functioning. Executive functioning refers to a group of neuro-psychological functions which include sustained attention, working memory, verbal fluency, as well as motor and mental processing speed. Individuals with ADHD have been shown to have deficits in executive functioning independent of IQ, co-occurring psychiatric disorders, gender, and ADHD subtype. "Recollect" is an application (App) based working memory training video game where participants conduct 3-different adaptive working memory tasks. In each of these tasks participants are presented with a set of stimuli to be remembered while playing a simple platform game where they help navigate an astronaut across the screen and dodge obstacles. Recollect has been designed for all age groups to an interesting, fun and effective brain-training activity. The memory tasks included in the game have been independently shown to improve working memory in a manner that transfers to untrained tasks. The purpose of this study is to evaluate the effects of playing Recollect versus Tetris for 20 minutes per day, 5 days per week over a 4 week period, on executive functioning deficits in individuals who have Adult ADHD.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      40 Participants Needed

      Parent-Educator Action Response for ADHD

      Chicago, Illinois
      The goal of this clinical trial is to learn if a new adjunctive intervention, Parent-Educator Action Response (PEAR), works to improve teacher and family engagement in school-based interventions for child attention deficit/hyperactivity disorder (ADHD) and disruptive behavior symptoms. This clinical trial will also be used to refine implementation procedures to inform a larger clinical trial.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Child Age, No Challenges, Language

      48 Participants Needed

      1234

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Adhd clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Adhd clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Adhd trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Adhd is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Adhd medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Adhd clinical trials?

      Most recently, we added MomMA Intervention for ADHD, Iron Supplementation for ADHD and Restless Sleep and Interaction Training for Childhood Behavior to the Power online platform.

      How to manage ADHD without Adderall?

      Think of ADHD care without Adderall as three pillars: 1) proven skills training such as cognitive-behavioral therapy or parent/teacher coaching, which meta-analyses show can meaningfully cut inattentive and impulsive symptoms; 2) daily habits that boost brain chemicals—consistent aerobic exercise, 7-9 hours of sleep, and a balanced, low-sugar diet—each backed by research to modestly improve focus; 3) targeted add-ons (omega-3 fish-oil supplements, mindfulness practice, or professionally guided neurofeedback) that have small but credible benefits for some people. Work with a clinician to combine, test, and adjust these pieces every few months so you know what is actually helping and can add non-stimulant medicines later if needed.

      Are we over diagnosing ADHD?

      Rates of ADHD diagnosis have climbed, and studies confirm that some children—especially the youngest in a class or from more advantaged families—get the label and medication they may not truly need. At the same time, girls, adults, and many minorities with real symptoms are often missed, so the issue is less “too much” diagnosis overall and more “diagnosis in the wrong people.” Asking for a full evaluation that checks symptoms in several settings and rules out sleep, mood, or learning problems is the best safeguard against both mistakes.

      What is the latest research on ADHD?

      Recent work is mapping ADHD on two fronts: cause and treatment. On the biology side, a 2023 genome-wide study involving >40 000 people pinpointed 30+ gene regions, MRI scans show disrupted communication between attention- and reward-circuits, and several studies find distinct gut-bacteria patterns in both kids and adults—together suggesting ADHD arises from a mix of genes, brain-network wiring and (still-early) gut influences. Translating this, clinicians now have newer options beyond classic stimulants—FDA-approved viloxazine XR, long-acting patches, the prescription video-game EndeavorRx, and small but promising trials of neurofeedback and cognitive training—so ask your doctor about standard medications plus these emerging tools that may soon allow more personalized care.

      Does Johnny Depp have ADHD?

      There is no credible public record—interview, court document, or medical statement—showing that Johnny Depp has been formally diagnosed with ADHD; the claim stems from unsourced online lists that repeat each other. Until Depp or a qualified clinician confirms otherwise, any statement that he “has ADHD” should be treated as unverified speculation; if you need information about ADHD, rely on a licensed health professional, not celebrity rumors.

      What is the 80 20 rule ADHD?

      For someone with ADHD, the 80/20 rule means spotting the 20 % of tasks or habits that create about 80 % of your desired results—then protecting time and attention to do those first, ideally when your medication or energy is at its peak. This cuts overwhelm because you give yourself permission to ignore low-impact busywork and instead break the high-impact tasks into small, doable steps (using timers, alerts, or an accountability partner). Think of it as a focusing lens, not a cure; pair it with your regular ADHD treatments and adjust the “vital 20 %” as your goals change.

      Is ADHD a disability?

      Yes—ADHD is treated as a disability when the symptoms are strong enough to “substantially limit” everyday activities like focusing, learning, or working, which is exactly how U.S. laws such as the ADA, Section 504, and Social Security define disability. A diagnosis alone isn’t enough; you need documentation that the condition is causing real-world problems, after which schools, employers, or benefit programs must consider reasonable supports (extra time, quiet workspace, flexible scheduling, etc.). If you think ADHD is holding you back, gather medical records and examples of how it affects your tasks and formally ask for accommodations or benefits under the relevant program.

      What makes ADHD people happy?

      Studies show that people with ADHD feel happiest when four things line up: (1) their core symptoms are tamed with medication and/or ADHD-specific therapy, (2) predictable routines, reminders, exercise, and good sleep cut daily chaos, (3) they spend real time in activities that match their high interests and creativity, and (4) they’re surrounded by family, friends, or support groups that understand ADHD rather than shame it. Put simply: treat the symptoms, externalize organization, lean into your passions, and stay connected to people who “get” you—those combined levers consistently raise quality-of-life scores for both kids and adults with ADHD.

      How much weight did you lose on ADHD medication?

      Weight loss on stimulant ADHD medicines is usually modest and highly individual—clinical trials show average drops of about 3–5 lb (1–2 kg) in the first month and roughly 6–10 lb (3–4 kg) over the first 3–6 months, with only one-third of people losing more than 5 % of their starting weight before the effect levels off. Weigh yourself (or your child) weekly; if you see more than a 10 % fall from baseline or a slowdown in growth, talk with the prescriber about dose timing, nutrition strategies, or switching to a non-stimulant option.

      What makes ADHD worse in adults?

      Anything that further strains the brain’s self-regulation system can flare adult ADHD: lack of sleep or exercise, chronic stress, unmanaged anxiety/depression, inconsistent medication or substance use, hormonal shifts, and chaotic, screen-heavy environments. Focus on the controllables—protect 7-9 h of sleep, move daily, eat regular balanced meals, keep spaces and schedules simple, treat co-existing mood issues, and take medication exactly as prescribed—then review persisting problems with your clinician.

      Is there still ADHD med shortage?

      Yes—into 2024 many pharmacies still report spot shortages of popular stimulant ADHD medicines, especially immediate-release Adderall, several methylphenidate/Concerta generics, and some Vyvanse doses, because factory slow-downs and federally capped production haven’t kept up with rising prescriptions. Availability varies week-to-week and by location, so call a few pharmacies early, ask if a different strength or brand is in stock, and have your prescriber ready to adjust the prescription or discuss a short-term non-stimulant alternative if needed.